[CIS PIDD] [cis-pidd] ADA2 deficiency - Infliximab dosage

[CIS-PIDD]

Professor Bodo,

Do you add mtx to your patients? What dosis?

Sent from my iPhone

> On 17 May 2017, at 14:57, CIS-PIDD <cis-pidd at lists.clinimmsoc.org> wrote:
> 
> Dear Sarah, dear all,
> I would like to caution:
> The fact that etanercept failed in IBD not necessarily predicts its capacity to work in gut inflammation in DADA2.
> The gut is a major source for ATP and therefore TNF-mediated gut inflammation in DADA2 is expected. 
> We all know that IBD is not IBD… (some 17% IBD patients have even responded to abatacept…:-)
> Yours, Bodo
> 
> ****************************************
> Univ.-Prof. Dr. med. B. Grimbacher
>  
> Scientific-Director
> CCI-Center for Chronic Immunodeficiency
> UNIVERSITÄTSKLINIKUM FREIBURG
> Tel.: 0761 270-77731  Fax: -77744
> Breisacherstraße 115, 79106 Freiburg
> bodo.grimbacher at uniklinik-freiburg.de 
> www.uniklinik-freiburg.de/cci
>  
> and 
>  
> Consultant Immunologist
> Institute of Immunity & Transplantation
> Dept of Immunology
> Royal Free Hospital
> UNIVERSITY COLLEGE LONDON
> Pond Street
> London NW3 2QG
> b.grimbacher at ucl.ac.uk
> www.centreforimmunodeficiency.com
> 
> Von: <cis-pidd at lyris.dundee.net> on behalf of CIS-PIDD <cis-pidd at lists.clinimmsoc.org>
> Antworten an: CIS-PIDD <cis-pidd at lyris.dundee.net>
> Datum: Wednesday 17 May 2017 02:58
> An: CIS-PIDD <cis-pidd at lyris.dundee.net>
> Betreff: Re: [cis-pidd] ADA2 deficiency - Infliximab dosage
> 
> If there is a significant G.I. inflammatory component, etanercept will not work. It failed in IBD clinical trials.  
> 
> Sarah C. Glover, DO, AGAF
> Director, Inflammatory Bowel and Celiac Disease Program
> Associate Professor of Medicine
> University of Florida
> PO Box 103643 
> Gainesville, FL 32610 
> http://gastroliver.medicine.ufl.edu/ibd/
> Phone (UF Health patient access center): 352-273-9400 
> Phone (IBD research): 352-265-8971
> Phone (Cell): 312-933-8039
> Fax 352-265-8979​
> 
> 
> Sent from my iPhone
> 
> On May 16, 2017, at 2:15 PM, CIS-PIDD <cis-pidd at lists.clinimmsoc.org> wrote:
> 
>> Dear Fabian,
>> 
>> Why would you use infliximab as opposed to etanercept? 
>> 
>> Isabelle Meyts, UZ Leuven
>> 
>> 
>> 
>> 
>> Op 16-mei-2017 om 17:00 heeft CIS-PIDD <cis-pidd at lists.clinimmsoc.org> het volgende geschreven:
>> 
>>> Dear all,
>>>  
>>> I am planning to treat an ADA2 deficient patient with Infliximab and would like to know the dosage and the dosing intervall already used sucessfully.
>>> Is it 5mg/kg at week 0, 2, 6 and thereafter every 8 weeks?
>>>  
>>> Thank you and best regards,
>>>  
>>> Fabian
>>>  
>>>  
>>> Fabian Hauck, MD, PhD
>>>  
>>> Head Immunodeficiency Unit and Immunological Diagnostics Laboratoy
>>> Pediatrics / Pediatric Hematology and Oncology / Immunology (DGfI)
>>>  
>>> Dr. von Hauner Children’s Hospital
>>> Klinikum der Universität München 
>>> Lindwurmstr. 4, 80337 München
>>> Germany
>>>  
>>> Tel.: +49 89 4400-53931
>>> Fax: +49 89 4400-53964
>>> E-Mail: fabian.hauck at med.uni-muenchen.de
>>>  
>>>  
>>> www.klinikum.uni-muenchen.de
>>>  
>>> <image001.png>
>>>  
>>> Das Klinikum der Universität München ist eine Anstalt des öffentlichen Rechts (AöR)
>>> The Klinikum der Universität München is an Institution under Public Law
>>>  
>>>  
>>>  
>>> 
>>> ---
>>> 
>>> You are currently subscribed to cis-pidd as: Isabelle.Meyts at uzleuven.be.
>>> 
>>> To unsubscribe click here: http://cts.dundee.net/u?id=96396636.15f0ef7c3f65602e498cc8265c1ae62d&n=T&l=cis-pidd&o=4376767
>>> 
>>> (It may be necessary to cut and paste the above URL if the line is broken)
>>> 
>>> or send a blank email to leave-4376767-96396636.15f0ef7c3f65602e498cc8265c1ae62d at lyris.dundee.net
>>> 
>> ---
>> 
>> You are currently subscribed to cis-pidd as: sarah.glover at medicine.ufl.edu.
>> 
>> To unsubscribe click here: http://cts.dundee.net/u?id=109023005.a6f267185a4a4f2c4ee42aedf0868c4d&n=T&l=cis-pidd&o=4377143
>> 
>> (It may be necessary to cut and paste the above URL if the line is broken)
>> 
>> or send a blank email to leave-4377143-109023005.a6f267185a4a4f2c4ee42aedf0868c4d at lyris.dundee.net
>> 
> ---
> 
> You are currently subscribed to cis-pidd as: bodo.grimbacher at uniklinik-freiburg.de.
> 
> To unsubscribe click here: http://cts.dundee.net/u?id=96396431.4f2a33ac30bfa58d3a76b5fb5b03d33a&n=T&l=cis-pidd&o=4377989
> 
> (It may be necessary to cut and paste the above URL if the line is broken)
> 
> or send a blank email to leave-4377989-96396431.4f2a33ac30bfa58d3a76b5fb5b03d33a at lyris.dundee.net
> 
> ---
> 
> You are currently subscribed to cis-pidd as: leonardo.oliveira.mendonca at gmail.com.
> 
> To unsubscribe click here: http://cts.dundee.net/u?id=96396764.5d5926a8e01f475d7bf6717a52d027f0&n=T&l=cis-pidd&o=4379373
> 
> (It may be necessary to cut and paste the above URL if the line is broken)
> 
> or send a blank email to leave-4379373-96396764.5d5926a8e01f475d7bf6717a52d027f0 at lyris.dundee.net

---
You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://cts.dundee.net/u?id=96396833.5a9591ccd1e327fe6bc4d1543298c482&n=T&l=cis-pidd&o=4379387
or send a blank email to leave-4379387-96396833.5a9591ccd1e327fe6bc4d1543298c482 at lyris.dundee.net
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://pairlist7.pair.net/pipermail/pagid/attachments/20170517/d3e3486f/attachment-0001.html>